1. Wellstein A. et al. Concentration kinetics of propranolol, bisoprolol and atenolol in humans assessed with chemical detection and a subtype selective adrenoreceptor. J Cardiovasc Pharmacol 1986; 8 (Suppl): 41.
2. Brixius K, Bundkirchen A, Bolck B et al. nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol 2001; 133 (8): 1330–8.
3. Leopold G. Balanced pharmacokinetics and metabolism of bisoprolol. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): 16–20.
4. Horikiri Y, Suzuki T, Mizobe M. Pharmacokinetics and metabolism of bisoprolol enantiomers in humans. J Pharm Sci 1998; 87 (3): 289–94.
5. Leopold G, Kutz K. Bisoprolol: pharmacokinetic profile. Rev Contemp Pharmacother 1997; 8: 35–43.
6. Руководство по кардиологии: учебное пособие в 3 т. Под ред. Г.И.Сторожакова, А.А.Горбаченкова. М.: ГЭОТАР-Медиа, 2008.
7. Cheung WK, Begg E, Dutta A et al. Dose proportionality of bisoprolol in man. Pharm Res 1988; 5 (Suppl.): S159.
8. Lithell H, Selinus I, Hosie J et al. Efficacy and safety of bisoprolol and atenolol in patients with mild to moderate hypertension: a double-blind, parallel group international multicentre study. Eur Heart J 1987; 8 (Suppl. M): 55–64.
9. Метелица В.И., Дуда С.Г., Горбунов В.М. и др. Антигипертензивный эффект нового кардиоселективного бета-адреноблокатора пролонгированного действия бисопролола по сравнению с пропранололом, метопрололом и плацебо. Экспер. и клин. фармакол. 1995; 58 (2): 32–4.
10. Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of trearment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). Eur Heart J 1987; 8: 103–13.
11. Benetos A, Adamopoulos C, Argyriadis P et al. Clinical results with bisoprolol 2.5 mg/hydrochlorothiazide 6.25 mg combination in systolic hypertension in the elderly J Hypertens 2002; 20 (Suppl. 1): S21–5.
12. United Kingdom Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13.
13. von Arnim T. Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. The TIBBS Investigators. J Am Coll Cardiol 1995; 25 (1): 231–8.
14. van de Ven LL, Vermeulen A, Tans JG et al. Which drug to choose for stable anginapectoris: a comparative study between bisoprolol and nitrates. Int J Cardiol 1995; 47 (3): 217–23.
15. Yusuf S, Lessem J, Pet J et al. Primary and secondary prevention of myocardial infarction and strokes. An update of randomly allocated controlled trials. J Hypertens 1993; 11 (Suppl. 4): 561–73.
16. de Muinck ED, Lie KI von Mengden HJ. Bisoprolol pilot studies in myocardial infarction. J Cardiovasc Pharmacol 1990; 16 (Suppl. 5): 5196–200.
17. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (3-й пересмотр). Под ред. Ф.Т.Агеева, Г.П.Арутюнова, В.Ю.Мареева и др. Серд. недостат. 2009; 2: 64–103.
18. The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: full text. Eur Heart J 2005; 26.
19. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2001; 104: 2996–3007.
20. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study. Circulation 1994; 90: 1765–73.
21. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999; 353: 9–13.
22. Possible clinical implications of the Cardiac Insufficiency Bisoprolol (CIBIS) III trial. Br J Cardiol 2005; 12: 448–54.
23. Беленков Ю.Н. Скворцов А.А., Мареев В.Ю. и др. Клинико-гемодинамические и нейрогормональные эффекты длительной терапии β-адреноблокатором бисопрололом больных с тяжелой хронической сердечной недостаточностью. Кардиология 2003; 43 (10): 10–21.
24. Иваненко В.В. Рязанцева Н.В., Тарасов Д.Л., Лопатин Ю.М. Влияние β1-адреноблокатора бисопролола на восстановление функции гибернирующего миокарда у больных с хронической сердечной недостаточностью ишемической этиологии. Кардиология 2004; 44 (7): 57–61.
25. Сторожаков Г.И., Гендлин Г.Е. Основные направления в лечении больных с хронической сердечной недостаточностью. Руководство для врачей-терапевтов, врачей общей практики. М.: Миклош, 2008.
26. Михайлова И.Е., Перепеч Н.Б. Бисопролол: фармакологические свойства и клиническое применение. Рус. мед. журн. 2004; 12 (4): 225.
27. Chen J, Redfort MJ, Wang Y et al. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 2001; 7: 1950–6.
28. Мелехов А.В. Состояние артериального сосудистого русла, микроциркуляции и биомеханики дыхания у больных с хронической сердечной недостаточностью.  Дис. ... канд. мед. наук. М., 2005.
29. Janka HU, Ziegler AG, Disselhoff G, Mehnert H. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): S96–9.
30. Prisant LM, Weir MR, Papademetriou V et al. Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. Am Heart J 1995; 130 (2): 359–66.
31. Prisant LM, Weir MR, Frishmanwh et al. Self reported Sexual Dysfunction in Men and Woman Treated With Bisoprolol, Hydrochlorothiazide, Enalapril, Placebo, or Bisoprolol/Hydrochlorothiazide. J Clin Hypertens 1999; 1: 22–6.
32. Cohn JN, Fowler MB, Bristow MB et al. for the US Carvedilol Heart Failure Study Group. Safety and efficacy of carvedilol in severe heart failure. J Card Fail 1997; 3: 173–9.
33. Packer M, Fowler MB, Roccker EB et al. for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group.
34. Ekman M, Zethraeus N, Dahlstrom U, Hoglund C. Cost-effectiveness of bisoprolol in chronic heart failure. Lakartidningen. 2002; 99 (7): 646–50.
35. Varney S. A cost-effectiveness analysis of bisoprolol for heart failure. Eur J Heart Fail 2001; 3 (3): 365–71.

Г.Е.Гендлин, С.Н.Борисов, А.В.Мелехов